# US 12,109,264 B2 · Motile sperm domain containing protein 2 and inflammation > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 12,109,264 B2 - Document ID: US12109264B2 - Status: Granted - Kind: B2 - Application number: 17/019,893 - Filed: 2020-09-14 - Published: 2021-03-18 - Granted: 2024-10-08 - Earliest claimed: 2015-07-31 - Assignees: ImmuneWalk Therapeutics, Inc. - Applicants: ImmuneWalk Therapeutics, Inc. - Inventors: Itzhak Mendel; Oshrat Propheta-Meiran; Yaniv Salem; Anat Shoham; Eyal Breitbart - Web page: https://patentgrep.com/patent/US12109264B2 ## CPC - A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines} - A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links - A61K 39/0008: {Antigens related to auto-immune diseases; Preparations to induce self-tolerance} - A61K 39/001102: {Receptors, cell surface antigens or cell surface determinants} - A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] - A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection - C07K 16/28: against receptors, cell surface antigens or cell surface determinants - A61K 48/0016: {wherein the nucleic acid is delivered as a 'naked' nucleic acid, i.e. not combined with an entity such as a cationic lipid} - A61K 2039/505: {comprising antibodies} - C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)} - C12N 2310/531: Stem-loop; Hairpin - Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) - Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE ## Abstract Disclosed herein are methods of treating, preventing, or reducing the incidence of an inflammatory disease or disorder and methods of inhibiting, preventing, or reducing the incidence of one or more activities in a cell with an inhibitor of a Motile Sperm Domain containing Protein 2 (MOSPD2). Also disclosed are inhibitors of MOSPD2 and pharmaceutical compositions containing MOSPD2 inhibitors. ## Claims ### Claim 1 A method of treating a chronic inflammatory disease or disorder in a subject, comprising administering to the subject an inhibitor of MOSPD2, wherein the inhibitor is an RNA silencing agent, and wherein the chronic inflammatory disease or disorder is rheumatoid arthritis, systemic lupus erythematosus, scleroderma, mixed connective tissue disease, polyarteritis nodosa, polymyositis/dermatomyositis, Sjogren's syndrome, Behcet's disease, multiple sclerosis, autoimmune diabetes, Hashimoto's disease, psoriasis, primary myxedema, pernicious anemia, myasthenia gravis, chronic active hepatitis, autoimmune hemolytic anemia, idiopathic thrombocytopenic purpura, uveitis, vasculitides, or heparin induced thrombocytopenia. ### Claim 2 (depends on 1) The method of claim 1, wherein the inhibitor is miRNA, siRNA, or shRNA. ### Claim 3 (depends on 2) The method of claim 2, wherein the inhibitor is shRNA. ### Claim 4 (depends on 1) The method of claim 1, wherein the subject is a human. ### Claim 5 (depends on 2) The method of claim 2, wherein the inhibitor is miRNA. ### Claim 6 (depends on 2) The method of claim 2, wherein the inhibitor is siRNA. ### Claim 7 (depends on 1) The method of claim 1, wherein the chronic inflammatory disease or disorder is rheumatoid arthritis. ### Claim 8 (depends on 1) The method of claim 1, wherein the chronic inflammatory disease or disorder is systemic lupus erythematosus. ### Claim 9 (depends on 1) The method of claim 1, wherein the chronic inflammatory disease or disorder is scleroderma. ### Claim 10 (depends on 1) The method of claim 1, wherein the chronic inflammatory disease or disorder is polyarteritis nodosa. ### Claim 11 (depends on 1) The method of claim 1, wherein the chronic inflammatory disease or disorder is multiple sclerosis. ### Claim 12 (depends on 1) The method of claim 1, wherein the chronic inflammatory disease or disorder is autoimmune diabetes. ### Claim 13 (depends on 1) The method of claim 1, wherein the chronic inflammatory disease or disorder is Hashimoto's disease. ### Claim 14 (depends on 1) The method of claim 1, wherein the chronic inflammatory disease or disorder is psoriasis. ### Claim 15 (depends on 1) The method of claim 1, wherein the chronic inflammatory disease or disorder is Behcet's disease. ### Claim 16 (depends on 1) The method of claim 1, wherein the chronic inflammatory disease or disorder is myasthenia gravis. ### Claim 17 (depends on 1) The method of claim 1, wherein the chronic inflammatory disease or disorder is chronic active hepatitis. ### Claim 18 (depends on 1) The method of claim 1, wherein the chronic inflammatory disease or disorder is vasculitides. ### Claim 19 (depends on 1) The method of claim 1, wherein the chronic inflammatory disease or disorder is idiopathic thrombocytopenia purpura. ### Claim 20 (depends on 1) The method of claim 1, wherein the chronic inflammatory disease or disorder is uveitis.